Immune mediation, B-cell depletion, and female leadership – ...
In a new pharmaphorum podcast, Aoife Brennan, CEO of Climb Bio, discusses the treatment of immune-mediated diseases.
NICE relents and backs Kisqali for wide use in breast cancer
Novartis' breast cancer therapy Kisqali has been cleared for NHS use in early breast cancer, an indication driving blockbuster sales of the drug.
EVERSANA unveils new AI-powered pharmacovigilance suite
EVERSANA has launched a new pharmacovigilance platform to answer the need for advanced analytics and AI in drug safety monitoring and risk management.
Digital twins and virtual trials: A new era in rare disease ...
Integrating digital twins and virtual trials with AI in clinical research will usher in a new era of drug development for rare diseases.
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
Unlocking the Potential of Targeting the Innate Immune Syste...
Ready to Catalyze the Next Wave of Inflammasome Therapies?
The Inaugural Market Access for CNS Therapeutics Summit Has ...
The only dedicated forum focused on tackling the unique commercial and reimbursement challenges facing treatments for neurodegeneration...
5th Oligonucleotides for CNS Summit
The Oligonucleotides for CNS Summit returns for its 5th year to address key challenges in durability, scalability, potency and CNS tropism
Immune Cell Engager Partnering & Investment Summit
Driving high ROI across immune cell engagers through strategic partnerships & investments, capitalizing on novel targets & asset tunability...
2nd ADC & Novel Conjugates Partnering & Investment Summit
Refine your strategy, sharpen your positioning, and meet the right partners - all at the most efficient networking event of the ADCconference calendar